SynSense is excited to announce that the company has successfully raised $27.7 million in our latest funding round, marking a pivotal milestone in our mission to revolutionize the computing landscape. As a leading-edge neuromorphic computing company, SynSense specializes in developing dedicated mixed-signal and fully digital neuromorphic processors that overcome the inherent limitations of traditional von Neumann architectures. These innovative processors deliver an unprecedented combination of ultra-low power consumption and low-latency performance, making them ideally suited for a wide range of advanced artificial intelligence (AI) edge computing applications. Founded in March 2017 and born from the groundbreaking research at the Institute of Neuroinformatics of the University of Zurich and ETH Zurich, SynSense has pioneered the development of “full-stack” custom neuromorphic processors. Our cutting-edge technology is set to transform industries by powering autonomous robots, providing always-on co-processors for mobile and embedded systems, enhancing wearable healthcare solutions, boosting security systems, and optimizing IoT applications and computing at the network edge. The recent infusion of capital is earmarked for accelerating our research and development efforts, scaling production capabilities, and expanding our market reach to meet the growing demand for energy-efficient AI processing units. Additionally, the funding will further strengthen the SynSense Group’s ecosystem, which includes iniVation—the original and leading provider of technology and solutions for high-performance neuromorphic vision. This strategic investment reinforces our commitment to delivering transformative computing solutions that not only push the boundaries of performance but also lay the foundation for a new era of smart, efficient, and adaptive technology.
SynSense Secures $27.7M to Accelerate the Future of Neuromorphic AI Edge Computing
Get the full SynSense company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Charm Health Skin Tag Remover
Charm Health Skin Tag Care emerges as a standout option for those looking to remove skin tags the gentle, non-invasive way. Formulated with natural ingredients and supported by positive user experiences, it provides a convenient alternative to traditional removal methods like freezing or surgical procedures.
$100.0K Unknown
today
BuildingIQ, Inc.
BuildingIQ (ASX:BIQ) helps building owners and operators worldwide lower energy use, increase building operations efficiency, and improve occupant comfort. We make this happen through out 5i Platform of technology-enabled services that power a better Internet of Things (IoT) approach for buildings. We have proven to reduce HVAC energy costs and made significant improvements in LEED or NABERS ratings, increased market value, and we help facilities teams operate buildings at lower cost with a higher level of service. BuildingIQ’s technology and service platform is built on the five pillars of data capture analysis, advanced modeling, measurement & verification, closed loop predictive control, and expert human analysis. These five pillars enable our services to deliver an optimize balance of energy savings, operational efficiency, and tenant comfort. Our platform ingests multiple, large and disparate data streams from buildings, meters, and other data sources; it then translates and models, and performs predictive analytics to inform our —and our partners’— services. The 5i Platform’s structured API fuels BuildingIQ services as well as those from our technology partners. Over time, the platform leverages machine learning to evolve along with our customers’ buildings. BuildingIQ was spun out from Australia’s National Labs and works closely with the US National Labs. Investors in BuildingIQ include the Venture Capital unit of Siemens Financial Services, Paladin Capital and Exto Partners.
$2.8M Series b
today
Config
Config was started in 2017 with two primary objectives. The first objective is to build a product company for the long term. A company where employees would want to work because they, and the work they do, matter. It’s not going to be a startup looking for funding with an exit strategy even before it started. A family owned company that can be passed down to the next generation. The second objective is to create a scholarship program for less fortunate kids. Kids who have the passion for learning but can’t go to school because they lack the financial means to do so. Seeing kids move on to good careers, helping improve their family’s quality of life, is what keeps us going. Config is a SaaS provider with a focus on managing configuration files. Earlier in 2017, we noticed a high demand for such a service, and the shortage of easy alternatives for programmers, system administrators and IT managers. Our service allows users to access their configuration files easily and quickly, across all their servers and environments, making for a more streamlined and hassle-free workflow. Config is committed to making a difference. As a family-owned business, we genuinely care about our legacy, and we strive to make a positive impact in our community. Config donates 20% of the company’s net income to educational scholarships for the benefits of less fortunate kids who can’t afford to go to school.
$27.0M Seed
today
Karat
Karat helps engineering leaders transform their organizations. As the trusted standard in measuring talent quality, Karat provides a powerful system for companies like PayPal, Atlassian and Citi who want to take control of how they hire top engineers, elevate their teams and contractors, and stay ahead. At the core of Karat’s system are live, expert-led interviews, analytics designed to give leaders maximum visibility, and the most robust interview performance dataset in the world. Coming soon: A new Human+AI way to interview technical talent in the AI era.
$110.0M Series c
today
DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor. The company is based on prominent international research from leading universities and funded by top Norwegian tech investors.
$10.8M Grant
today